Transgene SA (OTCMKTS:TRGNF – Get Free Report) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 4,349 shares. Based on an average daily volume of 282 shares, the short-interest ratio is presently 15.4 days.
Transgene Price Performance
OTCMKTS:TRGNF opened at $0.75 on Monday. The company has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $0.88. Transgene has a 12 month low of $0.75 and a 12 month high of $0.80.
Transgene Company Profile
Transgene is a French biotechnology company that develops immunotherapies, with a primary focus on treatments for cancer. Its research centers on therapeutic vaccines and oncolytic viruses—engineered viruses designed to target tumors and stimulate an immune response. The company’s pipeline includes candidates using viral-vector platforms, including personalized approaches intended to tailor treatment to the characteristics of an individual patient’s tumor. Transgene advances its programs through research and clinical development, often working with academic and industry partners.
Further Reading
- Five stocks we like better than Transgene
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Transgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgene and related companies with MarketBeat.com's FREE daily email newsletter.
